PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2012 January 1.
Published in final edited form as:
PMCID: PMC3144757
NIHMSID: NIHMS307016

Anti-platelet activity of valproic acid contributes to decreased soluble CD40L production in human immunodeficiency virus type 1-infected individuals

Abstract

CD40 ligand (CD40L) is a type II membrane glycoprotein of the tumor necrosis factor (TNF) family that is found on activated T cells, B cells, and platelets. We previously reported that the soluble form of this inflammatory mediator (sCD40L) is elevated in the plasma and cerebrospinal fluid of HIV-1 infected, cognitively impaired individuals. Here we demonstrate that the mood-stabilizing drug valproic acid (VPA) reduces sCD40L levels in plasma samples of HIV-1 infected patients (n=23) and in washed human platelets, which are the main source of circulating sCD40L. VPA also inhibited HIV-1 transactivator of transcription (Tat)-induced release of sCD40L and platelet factor 4 in C57BL/6 mice. The mechanism by which VPA was able to do so was investigated and herein we demonstrate that VPA, a known glycogen synthase kinase 3 beta (GSK3β) inhibitor, blocks platelet activating factor (PAF)-induced activation of GSK3β in platelets in a manner that alters sCD40L release from platelets. These data reveal that VPA has anti-platelet activity, and convey important implications for the potential of VPA as an adjunct therapy not only for cognitively impaired patients with HIV-1 infection, but also numerous inflammatory diseases for which such anti-platelet therapies are currently lacking.

Keywords: Platelets, Valproic Acid, HIV-1, Soluble CD40 Ligand, Glycogen Synthase Kinase 3 Beta, HIV Associated Neurocognitive Disorders

Introduction

CD40 ligand (CD40L; formerly known as CD154) is a type II membrane glycoprotein of the tumor necrosis factor (TNF) family that is found on activated T cells, B cells, and platelets (1). Classically, CD40L serves as a co-stimulatory molecule expressed on activated CD4+ T cells that binds to its receptor, CD40, on the surface of antigen presenting cells (APC) to induce activation. Binding of CD40L to CD40 on the surface of monocytes, for example, results in enhanced survival and secretion of cytokines such as TNFα and interleukins (IL-1 and IL-6) (1). Cleavage of CD40L produces a truncated form that is soluble, sCD40L, which retains its biological activity and acts as a cytokine (13). Activated platelets are believed to be the major source of circulating sCD40L, and are estimated to produce nearly 95% of the plasma sCD40L pool (4). Platelets and sCD40L are implicated in several inflammatory diseases, including cardiovascular disease, ischemia/reperfusion injury, and cerebral malaria (49). Increased numbers of activated platelets are also found in HIV-1-infected individuals (10), an event that leads to accumulation of sCD40L in the circulation regardless of highly active anti-retroviral therapy (HAART) followed by platelet decline (11, 12). Interestingly, a larger study within the North-East AIDS Dementia (NEAD) cohort indicated that the individuals with declining platelet counts are at greater risk for developing HIV-1-associated neurocognitive disorders (HAND) (13). In this context, sCD40L is present at significantly higher levels in both plasma and cerebrospinal fluid (CSF) samples of HAND patients (14). Our group previously reported that the mood stabilizing drug valproic acid (VPA) may have the potential to serve as an adjunct therapy for HAND, demonstrating a trend toward improved cognitive performance when tested in a controlled pilot patient study (15). Along these same lines, we also demonstrated neuroprotective effects of VPA in a mouse model of HIV-1 encephalitis (16). Herein, we now report that VPA reduces sCD40L levels in the plasma of HIV-1 infected individuals. Furthermore, we show that HIV-1 transactivator of transcription (Tat) induces a significant increase in sCD40L levels in C57BL/6 mice, an effect that is abolished in the presence of VPA. Our findings also suggest that the actions of VPA involve inhibition of sCD40L release from purified human platelets.

Previous reports indicate that VPA acts as a non-specific inhibitor of glycogen synthase kinase 3 beta (GSK3β) (15, 17), a multifaceted kinase involved in numerous cell processes and known to be present in platelets (18, 19). GSKβ is targeted by platelet activating factor (PAF) (20), which is upregulated during HIV-1 infection (21), and is believed to play a role in cytoskeletal rearrangement and lamellipodia formation in some cell types (22, 23). Based on this, we hypothesized that GSK3β is playing a similar role in platelets, as cytoskeletal rearrangement is an important step in platelet activation, and as such, may be the mechanism through which VPA reduces sCD40L levels. Consistent with this notion, we demonstrate here that treatment of human platelets with VPA reverses PAF-induced GSK3β activation. Furthermore, we also demonstrate that cytoskeletal rearrangement is required for sCD40L release, and that treatment of washed human platelets with GSK3β inhibitors attenuates platelet spreading, and therefore, cytoskeletal rearrangement. Taken all together, these findings highlight the potential of VPA as a candidate adjunct therapy in HAND, warranting further investigation.

Materials and Methods

Reagents and antibodies

HIV-1 Tat 1–72 was obtained from Philip Ray (University of Kentucky, Lexington, KY); carbamyl platelet-activating factor (cPAF; a non-hydrolyzable analog of PAF), valproic acid (VPA), lithium chloride (LiCl), fibrinogen, albumin from bovine serum (BSA), thrombin, cytochalasin E, and Tyrode's Salts solution were all purchased from Sigma Aldrich (St. Louis, MO); Prostacyclin (PGI2) was obtained from Cayman Chemical (Ann Arbor, MI); recombinant GSK3β was purchased from New England Biolabs (Ipswich, MA); recombinant glutathione S-transferase (GST) was synthesized as described (24). Antibodies against total GSK3β phospho(Ser-9)- GSK3β, total PKC, phospho(βII Ser660)-PKC (pan), hemagglutinin (HA), and α-Tubulin were purchased from BD Transduction Laboratories (San Jose, CA), Cell Signaling (Danvers, MA), and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), whereas FITC-conjugated anti human CD40L and phalloidin-Alexa Fluor 488 antibodies were obtained from Ancell Corporation (Bayport, MN) and Invitrogen (Carlsbad, CA), respectively.

Patient material

sCD40L levels were analyzed in the plasma of HIV-1-infected individuals using ELISA. These patients (n=23) were recruited in a previous study in which blood samples were periodically drawn before and after the treatment and plasma samples were cryo-preserved (25). The demographics, baseline clinical variables, and inclusion and exclusion criteria of the study subjects have been described (25). The baseline clinical variables of patients include viral load <400 copies/ml, and mean CD4+ cell count 443 ± 223.5 cells/μl. All patients were on a stable antiretroviral regimen containing efavirenz and/or nucleoside reverse transcriptase inhibitors for at least 4 weeks before and during the entire period (7 days) of these studies as described (25). All patients gave written consent for all procedures, which were approved by the University of Rochester Research Subjects Review Board.

Isolation of human platelets

Whole blood was obtained from healthy male and female donors, under University of Rochester IRB approval and with written informed consent in accordance with the Declaration of Helinski, by venipuncture into vacutainer tubes containing buffered citrate sodium (BD Biosciences, Franklin Lakes, NJ). Whole blood was then sequentially centrifuged to collect a purified platelet concentrate as described (26). Platelet purity was determined to be >99%.

ELISA

sCD40L was measured in plasma samples derived from HIV-1 infected individuals or supernatants from purified human platelets (9×107 cells/sample) using a human CD40L ELISA kit (R&D Systems, Minneapolis, MN) as outlined earlier (14). The concentrations of sCD40L (pg/ml) are presented as a mean (±SEM) of indicated replicates for each sample. The values were then compared by t-test with p<0.05 as statistically significant.

Nine-week-old male C57BL/6 mice (n=4 for each group) were given intraperitoneal (i.p.) injections of either saline (American Regent, Shirley, NY) or VPA (200 mg/kg of body weight) once a day for three days, as previously validated (16). Three hours post injection on the third day, 25 ng/g HIV-1 Tat was intravenously (i.v.) injected into the tail vein of each of the mice and, following 1h incubation, blood was collected via cardiac exsanguinations. Whole blood was sequentially centrifuged and platelet poor plasma (PPP) was collected. Soluble CD40L or platelet factor 4 (PF4) concentrations were measured in PPP samples using a mouse sCD40L ELISA kit (Bender Med Systems, San Diego, CA) or PF4 ELISA kit (R&D Systems, Minneapolis, MN). Samples were compared using one-way ANOVA followed by Bonferroni's test for multiple comparisons, which indicated statistical significance as p<0.05.

All animal experiments were carried out in accordance with the Animal Welfare Act and the National Institute of Health guidelines. The animal protocol was approved by the University Committee on Animal Resources of the University of Rochester Medical Center. The facilities and programs of the Vivarium and Division of Laboratory Animal Medicine of the School of Medicine and Dentistry are fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International (AAALAC) and are in compliance with state law, federal statute, and NIH policy.

Platelet Counts

Nine-week-old male C57BL/6 mice (n=5 for each group) were given fresh water, or that which was supplemented with 3.2 mg/mL VPA, for 18 days. Following treatment, mice were bled from the retro-orbital sinus and counts were performed using a Heska CBC-Diff Veterinary Analyzer (Fort Collins, CO).

Tail Bleeding Assays

Eight-week-old male C57BL/6 mice (n=5 for each group) were treated with VPA in their drinking water as described above. Following treatment, mice were anesthetized and were placed on a raised platform with tails protruding over the edge. Tails were positioned 5 mm above filter paper and a 2 mm cut was made in the tip of the tail. The bleeding time was recorded from the time bleeding starts until it stopped completely. Values were compared using an unpaired t-test that indicated statistical significance as p<0.001 (indicated as ***).

In Vitro Kinase assay

Purified human platelets (9×107 platelets/sample) were exposed to 20 nM cPAF alone or together with 0.6 mM VPA for 1h at 37°C. Lysates were prepared and immunoprecipitation was performed using antibodies specific to GSK3β. Immune complexes were incubated with substrate, a recombinant NFATc1 (rNFATC1), and 10 mCi γ[32P] ATP. Substrate rNFATC1 was generated by subcloning PCR amplification product encompassing amino acid region of 147–291 of human NFAT C1 into the pGEX-4T-3 expression plasmid (Amersham-Pharmacia Biotechnology, Arlington Heights, IL), followed by expression of glutathione S-transferase (GST) fusion protein in E.Coli and subsequent purification using previously described methods (20). GSK3β activity was measured by the incorporation of 32P at the GSK3β sensitive site of the rNFATC1 via densitometric analysis of autoradiograms (Image J software, NIH, Bethesda, MD). Data represents mean (± SEM) derived from two separate experiments performed in triplicate, **denotes p<0.01.

Platelet spreading

Purified human platelets (1×107 platelets/sample) treated with either VPA or lithium chloride (LiCl) for 1h at 37°C were incubated for 45 minutes on glass coverslips coated with fibrinogen (100 μg/mL) and blocked with 0.5 μg/mL BSA. Platelets were subsequently fixed with 4% paraformaldehyde. Alternatively, platelets were pretreated with VPA for 20 minutes, incubated on coated coverslips for 45 minutes, and then post-treated with vehicle, recombinant GST (as a control), or recombinant GSK3β proteins for 1h prior to fixation or lysis, as previously described (27). Briefly, recombinant proteins were added to pretreated, spread platelets in Tyrode's buffer containing dimethyl sulfoxide (<0.1%), as a vehicle for spontaneous uptake, and following 1h incubation, coverslips were washed to remove recombinant proteins and the cells were lysed. Immunoblotting was subsequently used to verify delivery of recombinant proteins. Spread and fixed platelets were stained using phalloidin-Alexa Fluor 488 (1:200 diluted in PBS with 0.01% triton) for 45 minutes at room temperature. Cells were mounted and visualized using an Olympus BX51 light microscope (Olympus, Melville, NY). Platelets were counted and analyzed based on their level of spreading and the percentages of each type of platelet were calculated for each treatment group; briefly, not spread indicates round platelets lacking filopodia, partially spread indicates the presence of filopodia but not lamellipodia, fully spread indicates the presence of lamellipodia. Statistical analysis was performed using one-way ANOVA followed by Bonferroni's test for multiple comparisons with p<0.05 as statistically significant. ***denotes p<0.001; **p<0.01; *p<0.05.

Scanning electron microscopy (SEM)

Platelets were treated and spread as outlined above. The coverslips (in a 12 well plate) seeded with platelets were fixed in a 0.1M sodium cacodylate buffered, 2.5% glutaraldehyde fixative overnight at 4°C, post-fixed in buffered 1.0% osmium tetroxide, rinsed in buffer, dehydrated in a graded series of ethanol to 100%, transitioned into hexamethyldisilizane (HMDS) to 3 changes of 100% HMDS, and finally allowed to dry overnight in a fume hood. The coverslips were mounted onto aluminum stubs and sputter coated with gold/platinum for 60 seconds. Digital images were taken with a Gatan imaging system on a Zeiss Supra Field Emission SEM.

Results

VPA treatment in HIV infected individuals is associated with a decrease in circulating sCD40L levels

VPA was previously found to be efficacious in both a pilot patient study as well as an HIV encephalitis mouse model in the context of HAND (15, 16, 25). Based on these results, and our previous findings that HIV-1 infected individuals with cognitive impairment had increased levels of sCD40L in their plasma and CSF (14), we tested whether VPA treatment would have an effect on the level of circulating sCD40L in HIV positive individuals. To do so, plasma samples were collected from 23 HIV-1 infected individuals that were receiving conventional antiretroviral regimens both before (at baseline), and after 7 days of VPA administration (250 mg twice a day orally). sCD40L levels were then measured by ELISA. As shown in Figure 1, patients receiving VPA treatment had significantly lower (approximately 50%) plasma levels of sCD40L at the end of the 7-day treatment course.

Figure 1
VPA treatment significantly reduces circulating levels of sCD40L in HIV-infected patients

VPA blocks HIV-1 Tat-mediated release of sCD40L in mice

To understand the mechanism through which VPA exerts its effect on sCD40L concentrations in HIV-1-infected patients, we examined the ability of VPA to inhibit HIV-1 Tat-mediated release of sCD40L in mice. Nine week old C57BL/6 mice (n=4 for each group) were given intraperitoneal injections of either saline or VPA for three days, and on the third day, 3 hours post injection, Tat or saline was administered intravenously and plasma was obtained. As revealed in Figure 2A, higher levels of sCD40L were detected in Tat-exposed mice, an effect that was abolished in the presence of VPA. Since sCD40L in plasma is believed to arise mainly from activated platelets (4), we speculated that VPA inhibits Tat-mediated platelet activation, thereby reducing the levels of circulating sCD40L. In order to test this notion, we used the same plasma samples to measure levels of platelet factor 4 (PF4), as PF4 represents a prominent chemokine released from platelets upon activation. Our results showed that VPA administration also blocks the Tat-mediated increase in PF4 levels (Figure 2B), suggesting an important role for platelets in this process.

Figure 2
HIV-1 Tat induces platelet activation in vivo, which is abolished in the presence of VPA

Previous reports have indicated that VPA may lead to the development of thrombocytopenia in patients undergoing VPA treatment (28, 29). To verify that the decrease in sCD40L and PF4 that we see in the presence of VPA was a result of VPA's ability to dampen platelet activation and not due to loss of platelets, and to avoid undesired platelet activation and subsequent platelet loss which may result due to various injection procedures, C57BL/6 mice were given drinking water supplemented with VPA for up to 18 days, during which time platelet counts were performed at regular intervals. Weight and volume of water consumed remained consistent for each group throughout the course of treatment (data not shown). Following oral administration of VPA, we saw no change in platelet numbers, indicating that VPA was able to dampen platelet activation without affecting platelet numbers in this model (Figure 2C). Following the 18-day oral administration of VPA, tail bleed experiments were also performed as a method to determine platelet functionality, since several reports have indicated that VPA may contribute to coagulation abnormalities (3032). Although we did see a significant increase in clotting time, mice receiving VPA were able to stop the bleeding, indicating that platelets were still functional (Figure 2D).

VPA inhibits sCD40L release from purified human platelets following exposure to PAF

We next tested whether VPA was able to inhibit sCD40L release directly from platelets. Human platelets isolated from healthy donors were treated with potent platelet activators thrombin and cPAF to induce sCD40L release, either alone or in the presence of VPA. In this case, the platelets were exposed to cPAF, since the biological action of Tat partly involves PAF receptor activation and the degree of neurologic dysfunction observed in HIV-1-infected patients correlates with increased levels of PAF in circulation (21, 33). As shown in Figure 3, both activators, thrombin and cPAF, were able to induce the release of sCD40L, however, this effect was significantly attenuated following treatment with VPA. It is noteworthy that the most effective dose of VPA used in this assay was equal or lower to concentrations measured in the plasma of individuals receiving the standard dose of this drug (15, 25).

Figure 3
VPA inhibits platelet release of sCD40L

Mechanism of platelet-deactivation by VPA

As previously mentioned, PAF, which is upregulated during HIV-1 infection, also activates GSK3β in mammalian cells. Furthermore, GSK3β is believed to play a role in cytoskeletal rearrangement and lamellipodia formation in some cell types (22, 23), a process that is important during platelet activation and cytokine release. In an effort to determine the mechanism by which VPA reduces the release of sCD40L from platelets, we first sought to determine if VPA inhibited PAF-induced activation of GSK3β in platelets. Purified human platelets isolated from healthy donors were treated with cPAF either alone, or in conjunction with VPA, and GSK3β–specific in vitro kinase assays were performed using a recombinant peptide substrate containing amino acid residues 147–291 of NFAT C1 molecules (20). Here we report that cPAF stimulates GSK3β activity in platelets in a manner that is blunted by addition of VPA (Figure 4A). Since the activity of GSK3β is negatively regulated by inducible phosphorylation of serine 9, we performed additional confirmatory immunoblot assays in which the same platelet lysates were used along with phospho(Ser-9)-specific GSK3β antibodies. Our results suggest that the pre-treatment with VPA indeed blocks cPAF-mediated activation of GSK3β in platelets (data not shown). To test whether the effects of VPA and cPAF were specific to GSK3β, the immunoblots were reprobed with phospho(βII Ser660)-specific PKC (pan) antibodies (phosphorylation of PKC at either Thr500, Thr641, or Ser660 residues indicate activation of this kinase). As shown in Figure 4B, we found no change in the phosphorylation status of PKC in either treatment groups, suggesting that the actions of VPA/cPAF are limited to a certain subset of kinases.

Figure 4
VPA reverses PAF-induced activation of GSK3β but does not alter PKC activity

Cytoskeletal rearrangement is important for sCD40L release from platelets, and is attenuated following VPA treatment

Spreading platelets undergo a morphological change resulting from cytoskeletal reorganization. As platelets adhere to an extracellular matrix, they extend filopodia followed by the formation of lamellipodia, which gives the platelets a flat, “ruffled” appearance (34, 35). This spread state for the platelet allows a greater number of interactions at the site of injury and with other platelets (7, 34, 35), while rearrangement allows movement and secretion of intracellular components needed upon activation (35). Based on this, and the results described in Figure 4, we next examined whether VPA treatment altered platelet spreading by modifying cytoskeletal rearrangement via GSK3β inhibition, and if this action of VPA lead to the inhibition of sCD40L release from platelets.

Initially, we verified whether cytoskeletal rearrangement was required for the release of sCD40L from platelets. To do so, platelets were exposed to cytochalasin E, an agent that binds to the growing end of actin filaments to prevent further polymerization (36), either alone or together with thrombin or cPAF, and levels of sCD40L were measured in the supernatant via ELISA. As depicted (Figure 5A), release of sCD40L from activated platelets was profoundly blocked by cytochalasin E pretreatment, suggesting that the restructuring of the cytoskeletal network was needed for the release of sCD40L (similar results were obtained following thrombin or cPAF treatments, and for this reason cPAF data are not shown in Figure 5A).

Figure 5
Cytoskeletal rearrangement is necessary for sCD40L release from platelets, and is attenuated following treatment with VPA

Finally, we performed platelet spreading assays to test if VPA exerts an effect on platelet cytoskeletal rearrangement. Platelets were left untreated or exposed to VPA or lithium chloride (LiCl), another well characterized inhibitor of GSK3β, and spread on fibrinogen coated coverslips to mimic a site of injury. Subsequently, the cells were either exposed to fluorescently labeled phalloidin (to stain F-actin polymers), or fixed and subjected to scanning electron microscopy (SEM). As determined by phalloidin-staining (Figure 5B, middle panel) and SEM (lower panel), platelets that were left untreated spread as expected and appeared large, flat, and “ruffled” with smooth edges (left panels, lamellipodia marked as `*'). In contrast, both VPA-, and LiCl-treated platelets appeared as if they were unable to spread completely, with visible filopodia, but lacking lamellipodia (right panels, filopodia are denoted as `[arrowhead]'). Quantification of the levels of spreading is shown in Figure 5C, which indicates that VPA treated platelets have altered platelet cytoskeletal rearrangement.

To further verify that GSK3β inhibition is the mechanism by which VPA alters platelet spreading and cytoskeletal rearrangement, spread platelets pretreated with VPA, or left untreated, were post-treated with recombinant GSK3β, recombinant GST as a control, or vehicle. Following post-treatment with GSK3β, a significantly larger percentage of platelets were fully spread compared to VPA treated platelets that received only vehicle as post-treatment. Thus, addition of exogenous GSK3β reversed the effect of VPA on platelet shape change. Addition of GST did not alter platelet spreading and mimicked results seen with vehicle post-treatment. Quantification of this process is shown in Figure 5D, along with immunoblot analysis to verify uptake of GSK3β by platelets.

Discussion

The use of HAART has made a significant impact on the lives of HIV-1 infected individuals. However, poor penetration of the CNS by these therapies has led to the need for adjunct treatments to address the growing number of individuals affected by neurologic consequences of HIV infection. We previously reported the presence of increased circulating levels of sCD40L in HIV-1 infected individuals with cognitive impairment as compared to infected individuals without cognitive impairment (14). Furthermore, in the same report, we demonstrated that CD40L potentiates the ability of HIV-1 Tat to activate microglia and monocytes (14). Therefore, attenuation of sCD40L levels may prove beneficial in the control of this aspect of the disease by helping to ameliorate the harmful effects of the virus within the CNS. Here we demonstrate that VPA is able to reduce plasma levels of sCD40L in both HIV infected individuals and in an in vivo mouse model. Considering the current widespread clinical use of VPA for conditions such as bipolar disorder and epilepsy, these results have important implications for the potential of VPA or similar drugs as adjunctive therapies for treatment of HAND.

HAND is widely believed to be an inflammatory disease; so it is fitting that elevated levels of CD40L have been implicated in numerous other inflammatory diseases, including cardiovascular disease (4, 37) and ischemia/reperfusion injury (8). In these instances the interaction of platelet-derived CD40L with endothelial cells is believed to induce inflammation. CD40, the receptor for CD40L, is constitutively expressed on endothelial cells and, upon ligation by CD40L, these cells become more conducive to monocytes that are being recruited in response to the inflammatory signals (7, 38). We speculate that the elevated levels of sCD40L observed in HIV-1 infected, cognitively impaired individuals are contributing to this inflammatory disorder in a similar fashion. Therapeutic targeting of CD40L is an attractive approach for the treatment of inflammatory disorders (39); however, CD40L is an important co-stimulatory molecule expressed on T cells and interfering with it could alter immune competence. Current strategies for targeting CD40L include cyclosporine A, an inhibitor of calcineurin that results in decreased CD40L expression in T cells, and anti-CD40L monoclonal antibodies; both of which have the potential to confer immunosuppression and thus would not be well-suited as adjunct therapies in HAND. The ability of VPA to decrease abnormally high plasma levels of sCD40L, without directly interfering with CD40 signaling, would therefore be advantageous in that desirable humoral immune responses would not be negatively affected. This further highlights the potential of VPA as a candidate adjunct therapy for HAND.

Some reports indicate that patients receiving VPA treatment may experience VPA-induced thrombocytopenia (28, 40); however, any thrombocytopenia observed appears to depend on variables such as gender, age, dosage, or low baseline platelet counts (28, 29, 40). Other published reports indicate that the dosage of VPA required to significantly increase risk of developing thrombocytopenia are above 40 mg/kg of body weight per day (41), considered a high dose. In our animal studies, mice received concentrations well above 40 mg/kg of body weight per day, however they had no evidence of thrombocytopenia. This discrepancy could be explained by the fact that mice possess higher platelet counts than humans, resulting in higher baseline platelet levels (42). The apparent risk of thrombocytopenia seems to vary depending on risk factors, and while this should be considered clinically, the widespread clinical use of this drug, demonstrating safety and tolerability, still makes it an attractive adjunct therapeutic candidate.

In order to determine the mechanism by which VPA reduces sCD40L release from platelets, we focused on GSK3β, which is involved in numerous signaling pathways and known to be inhibited by VPA. GSK3β has been implicated in HAND previously, as it was shown to be activated by PAF in neurons (20). Consistent with this notion, we now show here that activation of GSK3β is also induced by cPAF in platelets. Several reports have indicated that potent platelet activators such as thrombin, ADP, and collagen lead to the inhibition, rather than activation, of GSK3β (18, 19, 43). This phosphorylation-dependent inhibition of GSK3β involves activation of the upstream kinases phosphoinositide 3-kinase (PI3K) and protein kinase B (PKB/Akt) (19, 43). Consistent with these findings, we observed an increase in levels of phosphorylated GSK3β (indicative of inhibition) in response to thrombin treatment in platelets (data not shown), however, treatment with cPAF results in a significant decrease in phospho-GSK3β, suggesting that PAF activates a different signaling pathway to induce activation, rather than inhibition, of this kinase. Interestingly, we also see a significant increase in sCD40L release in response to thrombin, which would seemingly contradict our hypothesis, that active GSK3β is playing a role in sCD40L release. However, this paradox may be explained by the fact that there is a great deal of complexity in the regulatory pathways of this kinase. For example, reduced phosphorylation of GSK3β at serine 9 is usually associated with a 30–50% increase in kinase activity, which is apparently sufficient to induce biological effects (such as neuronal apoptosis) (44). Numerous signaling mechanisms target only a specific pool of the GSK3β present in the cells because of the sub-cellular distribution of both GSK3β and each regulatory molecule. Although GSK3β is traditionally considered a cytosolic protein, it is also present in other cellular compartments such as nuclei, mitochondria, and membrane lipid rafts (44, 45). An activity status of GSK3β is different in each compartment, such that the kinase moiety present in the nuclei, mitochondria and lipid raft is highly active (dephosphorylated at serine 9), and in contrast, cytosolic GSK3β is largely inactive. Thus, complete inhibition or activation of GSK3β in response to regulatory signaling events is highly unlikely. Indeed, we do not see complete inhibition of GSK3β in response to thrombin (data not shown). As previously mentioned, HIV-1 infection is associated with an increase in PAF (21), suggesting that platelets could be activated during infection in a manner that would allow aberrant GSK3β activation and therefore facilitate excess sCD40L release.

The data presented herein suggest that VPA is able to inhibit the release of sCD40L from platelets due to attenuated cytoskeletal rearrangement via GSK3β inhibition. This data is consistent with previous work that indicates that cytoskeletal rearrangement is indeed necessary for sCD40L release (46, 47). While it is still unclear whether GSK3β is acting directly on CD40L to inhibit it's trafficking to the cellular membrane (which occurs prior to its release), or rather, if its inhibition blocks the formation or movement of other CD40L containing vesicles to the surface prior to its cleavage, it is clear that platelet shape change is a necessary component of this process and inhibiting this can lead to altered CD40L solubilization.

The present report is also consistent with the previous findings by Barry and coworkers (19) that demonstrated an inhibition of platelet activity in vitro by short-term exposure of platelets to several GSK3β inhibitors (including lithium). In addition, Hayashi and Sudo (48) showed that treatment of platelets with various agents that elevate cAMP levels inhibit GSK3β thereby blocking platelet activity. Our study, as well as those of Barry et al. (19) and Hayashi and Sudo (48), contrast somewhat with the findings reported by Li et al. (18), who found that GSK3β works as a negative regulator of platelet function and thrombosis. In their report, they demonstrate that GSK3β+/− platelets exhibit agonist-dependent aggregation, ATP secretion, and fibrinogen binding, compared with GSK3β+/+ platelets, suggesting that GSK3β suppresses platelet function in vitro (18). There are, however, important differences between our experiments and those conducted by Li and coworkers. These include the fact that we have examined the effect of pharmacologic inhibition of GSK3β on platelet-derived sCD40L levels, while Li and colleagues determined the effect of genetic deletion of this molecule on thrombotic events (18). In addition, we have focused on the effect of VPA on platelet activation (and GSK3β) by effector molecules associated with HIV-1-infection (mainly Tat and PAF). In contrast, Li et al. studied platelet function in the context of non-pathogenic regulators of GSK3β. Thus, we hypothesize that the pathologic upregulation of GSK3β activity may lead to quite different effects on inflammatory mediators released by platelets.

Our group was the first to report the potential of VPA as an adjunct therapy for HIV-associated cognitive impairment (15), demonstrating not only a trend toward improved cognitive performance but also improvements in measures of brain metabolism when tested in a controlled pilot patient study (15). Along these same lines, neuroprotective effects of VPA in a murine model of HIV encephalitis were also previously reported (16). The results presented here demonstrate that VPA is able to reduce plasma levels of sCD40L in HIV infected individuals and indicate that this action is linked to the ability of VPA to inhibit GSK3β in platelets. The use of VPA in this context may confer therapeutic benefits not only for HAND, but also other inflammatory diseases, such as stroke, that are linked to platelet activation.

Acknowledgments

The authors would like to thank Dr. Neil Blumberg for helpful comments on this work. We are also grateful to the University of Rochester Electron Microscope Research Core, specifically Karen L. de Mesy Bentley and Gayle Schneider. We would like to thank the University of Rochester Division of Laboratory Animal Medicine, specifically Robin Westcott. Additionally, we would like to thank Mr. Randall M. Rossi for use of the Heska Veterinary Analyzer, as well as Dr. Jamie Bernard, Ms. Ann Casey, and Mr. Stephen Pollock for valuable assistance.

This work was supported by National Institutes of Health Grants: RO1 NS054578, RO1 NS066801, HL-RC1-100051, HL095467, ES01247, R01HL094547, R01HL093179, and R01HL093179-02S109.

Abbreviations used in this paper

HIV-1
HIV type 1
HAND
HIV associated neurocognitive disorders
sCD40L
soluble CD40 ligand
VPA
valproic acid
PAF
platelet activating factor
cPAF
carbamyl-PAF
GSK3β
glycogen synthase kinase 3 beta
Tat
HIV-1 transactivator of transcription

Footnotes

Conflict of interest disclosure: The authors declare no competing financial interests.

References

1. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol. 2000;67:2–17. [PubMed]
2. Mazzei GJ, Edgerton MD, Losberger C, Lecoanet-Henchoz S, Graber P, Durandy A, Gauchat JF, Bernard A, Allet B, Bonnefoy JY. Recombinant soluble trimeric CD40 ligand is biologically active. J Biol Chem. 1995;270:7025–7028. [PubMed]
3. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749–1754. [PubMed]
4. Andre P, Nannizzi-Alaimo L, Prasad SK, Phillips DR. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation. 2002;106:896–899. [PubMed]
5. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest. 2005;115:3378–3384. [PMC free article] [PubMed]
6. Mannel DN, Grau GE. Role of platelet adhesion in homeostasis and immunopathology. Mol Pathol. 1997;50:175–185. [PMC free article] [PubMed]
7. Tabuchi A, Kuebler WM. Endothelium-platelet interactions in inflammatory lung disease. Vascul Pharmacol. 2008;49:141–150. [PubMed]
8. Ishikawa M, Vowinkel T, Stokes KY, Arumugam TV, Yilmaz G, Nanda A, Granger DN. CD40/CD40 ligand signaling in mouse cerebral microvasculature after focal ischemia/reperfusion. Circulation. 2005;111:1690–1696. [PubMed]
9. Piguet PF, Kan CD, Vesin C, Rochat A, Donati Y, Barazzone C. Role of CD40-CD40L in mouse severe malaria. Am J Pathol. 2001;159:733–742. [PubMed]
10. Holme PA, Muller F, Solum NO, Brosstad F, Froland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 1998;12:79–89. [PubMed]
11. Wolf K, Tsakiris DA, Weber R, Erb P, Battegay M. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002;185:456–462. [PubMed]
12. Flaujac C, Boukour S, Cramer-Borde E. Platelets and viruses: an ambivalent relationship. Cell Mol Life Sci. 67:545–556. [PubMed]
13. Wachtman LM, Skolasky RL, Tarwater PM, Esposito D, Schifitto G, Marder K, McDermott MP, Cohen BA, Nath A, Sacktor N, Epstein LG, Mankowski JL, McArthur JC. Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia. Arch Neurol. 2007;64:1264–1272. [PubMed]
14. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, Dewhurst S, Maggirwar SB. Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol. 2007;178:3226–3236. [PubMed]
15. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, Gendelman HE, Boska M, Gelbard H. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology. 2006;66:919–921. [PubMed]
16. Dou H, Birusingh K, Faraci J, Gorantla S, Poluektova LY, Maggirwar SB, Dewhurst S, Gelbard HA, Gendelman HE. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci. 2003;23:9162–9170. [PubMed]
17. Chen G, Huang LD, Jiang YM, Manji HK. The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem. 1999;72:1327–1330. [PubMed]
18. Li D, August S, Woulfe DS. GSK3beta is a negative regulator of platelet function and thrombosis. Blood. 2008;111:3522–3530. [PubMed]
19. Barry FA, Graham GJ, Fry MJ, Gibbins JM. Regulation of glycogen synthase kinase 3 in human platelets: a possible role in platelet function? FEBS Lett. 2003;553:173–178. [PubMed]
20. Maggirwar SB, Tong N, Ramirez S, Gelbard HA, Dewhurst S. HIV-1 Tat-mediated activation of glycogen synthase kinase-3beta contributes to Tat-mediated neurotoxicity. J Neurochem. 1999;73:578–586. [PubMed]
21. Gelbard HA, Nottet HS, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang D, et al. Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol. 1994;68:4628–4635. [PMC free article] [PubMed]
22. Hall AC, Brennan A, Goold RG, Cleverley K, Lucas FR, Gordon-Weeks PR, Salinas PC. Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol Cell Neurosci. 2002;20:257–270. [PubMed]
23. Koivisto L, Alavian K, Hakkinen L, Pelech S, McCulloch CA, Larjava H. Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes. J Cell Sci. 2003;116:3749–3760. [PubMed]
24. Sanchez JF, Sniderhan LF, Williamson AL, Fan S, Chakraborty-Sett S, Maggirwar SB. Glycogen synthase kinase 3beta-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor kappaB signaling. Mol Cell Biol. 2003;23:4649–4662. [PMC free article] [PubMed]
25. DiCenzo R, Peterson D, Cruttenden K, Morse G, Riggs G, Gelbard H, Schifitto G. Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4328–4331. [PMC free article] [PubMed]
26. O'Brien JJ, Spinelli SL, Tober J, Blumberg N, Francis CW, Taubman MB, Palis J, Seweryniak KE, Gertz JM, Phipps RP. 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes. Blood. 2008;112:4051–4060. [PubMed]
27. Spinelli SL, Casey AE, Pollock SJ, Gertz JM, McMillan DH, Narasipura SD, Mody NA, King MR, Maggirwar SB, Francis CW, Taubman MB, Blumberg N, Phipps RP. Platelets and megakaryocytes contain functional nuclear factor-kappaB. Arterioscler Thromb Vasc Biol. 2010;30:591–598. [PMC free article] [PubMed]
28. Nasreddine W, Beydoun A. Valproate-induced thrombocytopenia: a prospective monotherapy study. Epilepsia. 2008;49:438–445. [PubMed]
29. De Berardis D, Campanella D, Matera V, Gambi F, La Rovere R, Sepede G, Grimaldi MR, Pacilli AM, Salerno RM, Ferro FM. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. J Clin Psychopharmacol. 2003;23:451–458. [PubMed]
30. Koenig S, Gerstner T, Keller A, Teich M, Longin E, Dempfle CE. High incidence of vaproate-induced coagulation disorders in children receiving valproic acid: a prospective study. Blood Coagul Fibrinolysis. 2008;19:375–382. [PubMed]
31. Gerstner T, Teich M, Bell N, Longin E, Dempfle CE, Brand J, Konig S. Valproate-associated coagulopathies are frequent and variable in children. Epilepsia. 2006;47:1136–1143. [PubMed]
32. Serdaroglu G, Tutuncuoglu S, Kavakli K, Tekgul H. Coagulation abnormalities and acquired von Willebrand's disease type 1 in children receiving valproic acid. J Child Neurol. 2002;17:41–43. [PubMed]
33. Perry SW, Hamilton JA, Tjoelker LW, Dbaibo G, Dzenko KA, Epstein LG, Hannun Y, Whittaker JS, Dewhurst S, Gelbard HA. Platelet-activating factor receptor activation. An initiator step in HIV-1 neuropathogenesis. J Biol Chem. 1998;273:17660–17664. [PubMed]
34. McCarty OJ, Larson MK, Auger JM, Kalia N, Atkinson BT, Pearce AC, Ruf S, Henderson RB, Tybulewicz VL, Machesky LM, Watson SP. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem. 2005;280:39474–39484. [PMC free article] [PubMed]
35. Michelson AD. Platelets. Academic Press/Elsevier; Amsterdam: 2007.
36. Fox JE, Phillips DR. Inhibition of actin polymerization in blood platelets by cytochalasins. Nature. 1981;292:650–652. [PubMed]
37. Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 2008;14:530–538. [PubMed]
38. Ramirez SH, Fan S, Dykstra H, Reichenbach N, Del Valle L, Potula R, Phipps RP, Maggirwar SB, Persidsky Y. Dyad of CD40/CD40 ligand fosters neuroinflammation at the blood-brain barrier and is regulated via JNK signaling: implications for HIV-1 encephalitis. J Neurosci. 30:9454–9464. [PMC free article] [PubMed]
39. Daoussis D, Andonopoulos AP, Liossis SN. Targeting CD40L: a promising therapeutic approach. Clin Diagn Lab Immunol. 2004;11:635–641. [PMC free article] [PubMed]
40. Conley EL, Coley KC, Pollock BG, Dapos SV, Maxwell R, Branch RA. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy. 2001;21:1325–1330. [PubMed]
41. Ko CH, Kong CK, Tse PW. Valproic acid and thrombocytopenia: cross-sectional study. Hong Kong Med J. 2001;7:15–21. [PubMed]
42. Schmitt A, Guichard J, Masse JM, Debili N, Cramer EM. Of mice and men: comparison of the ultrastructure of megakaryocytes and platelets. Exp Hematol. 2001;29:1295–1302. [PubMed]
43. Kim S, Jin J, Kunapuli SP. Relative contribution of G-protein-coupled pathways to protease-activated receptor-mediated Akt phosphorylation in platelets. Blood. 2006;107:947–954. [PubMed]
44. Sui Z, Kovacs AD, Maggirwar SB. Recruitment of active glycogen synthase kinase-3 into neuronal lipid rafts. Biochem Biophys Res Commun. 2006;345:1643–1648. [PubMed]
45. Bijur GN, Jope RS. Glycogen synthase kinase-3 beta is highly activated in nuclei and mitochondria. Neuroreport. 2003;14:2415–2419. [PubMed]
46. Otterdal K, Pedersen TM, Solum NO. Release of soluble CD40 ligand after platelet activation: studies on the solubilization phase. Thromb Res. 2004;114:167–177. [PubMed]
47. Furman MI, Krueger LA, Linden MD, Barnard MR, Frelinger AL, 3rd, Michelson AD. Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. J Am Coll Cardiol. 2004;43:2319–2325. [PubMed]
48. Hayashi H, Sudo T. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets. Thromb Haemost. 2009;102:327–335. [PubMed]